+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations
R

Actively Recruiting

Researchers are evaluating whether spesolimab helps adults with ulcerative pyoderma gangrenosum PG, a skin condition causing ulcers. The study focuses on whether spesolimab leads to the closure of PG ulcers and compares this with a placebo. This phase 3 clinical trial is randomized, double-blind, and placebo-controlled, enrolling adults with at least one ulcer between 5 cm and 80 cm in size. Participants are randomly assigned to receive either spesolimab or a placebo infusion every 4 weeks. In the first part of the study, all participants also take corticosteroid medicine by mouth for 8 weeks. In the second part, those without open ulcers are again randomly assigned to spesolimab or placebo, while participants with open ulcers receive spesolimab. The study includes two treatment phases to evaluate the effects under different conditions. Participants stay in the trial for about 1.5 years, attending around 20 study visits. During visits, doctors examine the skin for signs of PG, monitor overall health, and watch for any side effects. The main outcome is the complete closure of the target PG ulcer up to week 26, confirmed at a later visit. Secondary outcomes include pain reduction and quality of life improvements. The study compares results between groups to assess the treatments impact and monitors participants safety throughout.

Age: 18Years +All GendersPhase 3
104 locations
E

Actively Recruiting

This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.

Age: 18Years +All GendersPhase 3
473 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ficerafusp alfa combined with pembrolizumab compared to placebo with pembrolizumab in adults with first-line PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma HNSCC. This study targets two cancer drivers, EGFR and TGF-beta, to address tumor growth and spread. It includes phase 2 to find the best dose and phase 3 to compare treatment outcomes. In phase 2, participants are randomly assigned to one of three groups ficerafusp alfa 1500 mg weekly plus pembrolizumab every three weeks, ficerafusp alfa 750 mg weekly plus pembrolizumab every three weeks, or placebo weekly plus pembrolizumab every three weeks. Phase 3 uses the optimal dose of ficerafusp alfa with pembrolizumab versus placebo with pembrolizumab in a 21 ratio. Treatments continue with scheduled dosing during each phase. Participants undergo regular assessments including scans to measure tumor response by RECIST 1.1 criteria, safety monitoring for side effects, and quality of life questionnaires. The study tracks objective response rate, overall survival, progression-free survival, and other measures over up to three years. Safety is closely monitored for treatment-related adverse events during and after therapy. Total participation may last several years depending on treatment and follow-up.

Age: 18Years +All GendersPhase 2Phase 3
231 locations